How do I install the Endo Lipoprotein A Threshold Cvd Risk Enhancement skill?

Run npx skillmds@latest add dromlakhani/endo-lipoprotein-a-threshold-cvd-risk-enhancement in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Endo Lipoprotein A Threshold Cvd Risk Enhancement safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Endo Lipoprotein A Threshold Cvd Risk Enhancement?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Endo Lipoprotein A Threshold Cvd Risk Enhancement free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Endo Lipoprotein A Threshold Cvd Risk Enhancement?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Endo Lipoprotein A Threshold Cvd Risk Enhancement by dromlakhani

Name: Endo Lipoprotein A Threshold Cvd Risk Enhancement
Rating: 4.2 (5 reviews)
Author: dromlakhani

Endo Lipoprotein A Threshold Cvd Risk Enhancement

Defines lipoprotein(a) ≥50 mg/dL (125 nmol/L) as a cardiovascular risk-enhancing factor for atherosclerotic cardiovascular disease. Triggered by Lp(a) measurement showing ≥50 mg/dL, assessing Lp(a)'s contribution to CVD risk, or using the Lp(a) threshold for risk stratification.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Lipoprotein(a) level ≥50 mg/dL as cardiovascular risk-enhancing factor

STEP 1 — Gather Information

Collect personal/family history of premature ASCVD, personal ASCVD, or family history of high Lp(a); obtain Lp(a) level (mg/dL or nmol/L) via immunoassay (fasting or nonfasting acceptable).

STEP 2 — Rule In / Rule Out

If Lp(a) ≥50 mg/dL (≥125 nmol/L), rule in as elevated Lp(a); otherwise rule out.

STEP 3 — Classify or Stratify

If Lp(a) elevated, classify as a risk-enhancing factor; integrate with overall 10-year ASCVD risk (Pooled Cohort Equations) and other risk-enhancing factors.

STEP 4 — Decide

For borderline/intermediate risk (5–19.9% 10-year ASCVD) with elevated Lp(a), consider CAC scoring to guide statin initiation; if high risk (>20%), intensify LDL-C–lowering therapy regardless of CAC.

Clinical Guardrails / Mimics / Pitfalls

Lp(a) testing need not be repeated if previously measured; lowering Lp(a) not proven to reduce ASCVD risk; do not base statin decisions solely on Lp(a); Lp(a) unaffected by fasting status.

Concrete Clinical Example

55‑year‑old man with father’s MI at 58, LDL‑C 130 mg/dL, 10‑year ASCVD risk 12%, Lp(a) 80 mg/dL → elevated Lp(a) → intermediate risk + risk‑enhancing factor → CAC score obtained; CAC=120 → initiate moderate‑intensity statin.

Source: Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674

TODO: consider adding scripts/calc.py for the endo-lipoprotein-a-threshold-cvd-risk-enhancement calculator

---name: endo-lipoprotein-a-threshold-cvd-risk-enhancementdescription: Defines lipoprotein(a) ≥50 mg/dL (125 nmol/L) as a cardiovascular risk-enhancing factor for atherosclerotic cardiovascular disease. Triggered by Lp(a) measurement showing ≥50 mg/dL, assessing Lp(a)'s contribution to CVD risk, or using the Lp(a) threshold for risk stratification.---# Lipoprotein(a) level ≥50 mg/dL as cardiovascular risk-enhancing factor## STEP 1 — Gather InformationCollect personal/family history of premature ASCVD, personal ASCVD, or family history of high Lp(a); obtain Lp(a) level (mg/dL or nmol/L) via immunoassay (fasting or nonfasting acceptable).## STEP 2 — Rule In / Rule OutIf Lp(a) ≥50 mg/dL (≥125 nmol/L), rule in as elevated Lp(a); otherwise rule out.## STEP 3 — Classify or StratifyIf Lp(a) elevated, classify as a risk-enhancing factor; integrate with overall 10-year ASCVD risk (Pooled Cohort Equations) and other risk-enhancing factors.## STEP 4 — DecideFor borderline/intermediate risk (5–19.9% 10-year ASCVD) with elevated Lp(a), consider CAC scoring to guide statin initiation; if high risk (>20%), intensify LDL-C–lowering therapy regardless of CAC.## Clinical Guardrails / Mimics / PitfallsLp(a) testing need not be repeated if previously measured; lowering Lp(a) not proven to reduce ASCVD risk; do not base statin decisions solely on Lp(a); Lp(a) unaffected by fasting status.## Concrete Clinical Example55‑year‑old man with father’s MI at 58, LDL‑C 130 mg/dL, 10‑year ASCVD risk 12%, Lp(a) 80 mg/dL → elevated Lp(a) → intermediate risk + risk‑enhancing factor → CAC score obtained; CAC=120 → initiate moderate‑intensity statin.**Source:** Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674> **TODO:** consider adding scripts/calc.py for the endo-lipoprotein-a-threshold-cvd-risk-enhancement calculator

Frequently asked questions